Amani Therapeutics
Recent Finacing
Series A
Recent Raise
$25M
Amani Therapeutics is a newly formed biotechnology company developing AM-01, a fixed-dose combination of clozapine and a Phase 3–ready novel chemical entity licensed from AstraZeneca for serious neuropsychiatric disorders.
